374 related articles for article (PubMed ID: 24103141)
21. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
22. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
Khunti K; Cos X; Rutten G
Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
[TBL] [Abstract][Full Text] [Related]
23. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
Berard L; MacNeill G
Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
[TBL] [Abstract][Full Text] [Related]
24. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
25. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus.
Pfützner A; Hermanns N; Funke K; Forst T; Behnke T; Bitton G; Nagar R; Raz I; Haak T
Curr Med Res Opin; 2014 May; 30(5):753-60. PubMed ID: 24392996
[TBL] [Abstract][Full Text] [Related]
26. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
Strojek K; Bebakar WM; Khutsoane DT; Pesic M; Smahelová A; Thomsen HF; Kalra S
Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654
[TBL] [Abstract][Full Text] [Related]
27. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
29. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
30. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
Nimri R; Lebenthal Y; Shalitin S; Benzaquen H; Demol S; Phillip M
Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
[TBL] [Abstract][Full Text] [Related]
31. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
Meneghini L; Koenen C; Weng W; Selam JL
Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
[TBL] [Abstract][Full Text] [Related]
32. [Hypoglycemia].
Gupta PS; Green AN; Chowdhury TA
Praxis (Bern 1994); 2011 Oct; 100(21):1303-5. PubMed ID: 22012756
[No Abstract] [Full Text] [Related]
33. Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.
Damci T; Emral R; Svendsen AL; Balkir T; Vora J;
BMC Endocr Disord; 2014 Jul; 14():61. PubMed ID: 25048824
[TBL] [Abstract][Full Text] [Related]
34. Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors.
Zhang T; Ji L; Gao Y; Zhang P; Zhu D; Li X; Ji J; Zhao F; Zhang H; Guo X
Diabetes Technol Ther; 2017 Nov; 19(11):675-684. PubMed ID: 29090977
[TBL] [Abstract][Full Text] [Related]
35. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study.
Kesavadev J; Joshi SR
J Assoc Physicians India; 2013 Jan; 61(1 Suppl):28-30. PubMed ID: 24482985
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.
Soewondo P; Kshanti IA; Pramono RB; Langi YA; Dalem-Pemayun TG
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S47-53. PubMed ID: 23647719
[TBL] [Abstract][Full Text] [Related]
37. Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE).
Karnieli E; Baeres FM; Dzida G; Ji Q; Ligthelm R; Ross S; Svendsen AL; Yale JF;
Drugs Aging; 2013 Mar; 30(3):167-75. PubMed ID: 23371395
[TBL] [Abstract][Full Text] [Related]
38. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.
Paul SK; Maggs D; Klein K; Best JH
J Diabetes; 2015 Jan; 7(1):60-7. PubMed ID: 25168883
[TBL] [Abstract][Full Text] [Related]
39. Reconsideration of severe hypoglycemic events in the treat-to-target trial.
Dailey G; Strange P; Riddle M
Diabetes Technol Ther; 2009 Aug; 11(8):477-9. PubMed ID: 19698059
[TBL] [Abstract][Full Text] [Related]
40. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.
Perriello G; Caputo S; De Pergola G; Di Carlo A; Grassi G; Lapolla A; Pata P; Solerte SB; Zaccardi F
Expert Opin Pharmacother; 2011 Nov; 12(16):2449-55. PubMed ID: 21988213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
